Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:51PM ET
3.90
Dollar change
+0.04
Percentage change
1.04
%
Index- P/E- EPS (ttm)-1.47 Insider Own19.44% Shs Outstand18.42M Perf Week8.64%
Market Cap72.50M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.97M Perf Month33.56%
Income-27.16M PEG- EPS next Q-0.21 Inst Own1.64% Short Float1.75% Perf Quarter39.29%
Sales0.00M P/S- EPS this Y36.76% Inst Trans-13.30% Short Ratio2.74 Perf Half Y143.75%
Book/sh2.09 P/B1.87 EPS next Y- ROA-45.52% Short Interest0.26M Perf Year13.04%
Cash/sh1.65 P/C2.37 EPS next 5Y- ROE-53.23% 52W Range1.20 - 4.37 Perf YTD44.44%
Dividend Est.- P/FCF- EPS past 5Y34.79% ROI-63.77% 52W High-10.76% Beta1.02
Dividend TTM- Quick Ratio7.34 Sales past 5Y0.00% Gross Margin- 52W Low225.00% ATR (14)0.34
Dividend Ex-Date- Current Ratio7.34 EPS Y/Y TTM5.85% Oper. Margin0.00% RSI (14)55.50 Volatility10.22% 9.72%
Employees77 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.00
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q-2.86% Payout- Rel Volume1.63 Prev Close3.86
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume95.60K Price3.90
SMA203.33% SMA5020.24% SMA20060.68% Trades Volume84,979 Change1.04%
Date Action Analyst Rating Change Price Target Change
Mar-02-21Reiterated H.C. Wainwright Buy $22 → $33
Mar-22-24 10:50AM
Feb-26-24 08:30AM
Feb-21-24 08:30AM
Feb-07-24 08:00AM
Jan-17-24 08:00AM
08:00AM Loading…
Dec-20-23 08:00AM
Nov-21-23 07:00AM
Sep-11-23 08:00AM
Sep-07-23 08:00AM
Aug-02-23 08:00AM
Jul-31-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 08:00AM
May-31-23 08:04AM
May-08-23 08:00AM
10:18AM Loading…
Apr-20-23 10:18AM
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-14-23 09:40AM
Apr-12-23 10:45AM
Apr-10-23 03:07AM
Apr-04-23 08:00AM
Apr-03-23 08:00AM
Mar-20-23 08:00AM
Feb-23-23 08:00AM
Feb-15-23 08:00AM
Jan-25-23 08:37AM
Jan-04-23 08:00AM
Dec-05-22 08:00AM
Dec-02-22 08:00AM
02:00PM Loading…
Dec-01-22 02:00PM
Nov-28-22 08:00AM
Nov-15-22 08:00AM
Nov-11-22 09:05AM
Nov-10-22 08:00AM
Oct-03-22 08:13AM
Sep-13-22 08:00AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-24-22 08:00AM
Aug-22-22 08:00AM
Aug-17-22 08:00AM
Aug-03-22 08:15AM
Jul-12-22 09:05AM
Jul-06-22 08:37AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
Jun-04-22 09:45AM
May-31-22 08:00AM
May-25-22 08:00AM
May-23-22 08:00AM
May-19-22 08:00AM
May-10-22 08:00AM
May-09-22 09:05AM
May-05-22 08:37AM
May-02-22 08:00AM
Apr-29-22 08:41AM
Apr-13-22 10:25AM
Mar-08-22 08:00AM
Mar-01-22 07:30AM
Feb-22-22 08:00AM
Jan-03-22 08:00AM
Dec-26-21 07:22AM
Dec-14-21 03:26PM
Dec-13-21 08:00AM
Dec-07-21 08:00AM
Dec-06-21 08:00AM
Nov-22-21 08:00AM
Nov-10-21 08:00AM
Nov-04-21 08:00AM
Oct-12-21 08:00AM
Oct-05-21 08:00AM
Oct-04-21 08:00AM
Sep-29-21 08:48AM
Sep-27-21 06:38AM
Sep-23-21 10:02AM
Sep-22-21 06:00AM
Sep-09-21 08:00AM
Sep-03-21 12:00PM
Aug-16-21 02:32PM
12:13PM
08:31AM
08:20AM
07:20AM
07:07AM
Aug-15-21 06:00AM
Aug-09-21 08:00AM
Aug-02-21 08:00AM
Jul-21-21 08:00AM
Jul-14-21 08:00AM
Jul-12-21 08:00AM
Jun-29-21 02:28AM
Jun-16-21 08:00AM
Jun-15-21 08:00AM
Jun-03-21 08:00AM
Jun-01-21 08:00AM
May-18-21 08:00AM
Mar-22-21 08:00AM
Mar-09-21 08:00AM
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.